Blackburn Kelly 4

What Happened Blackburn Kelly, Executive Vice President, Clinical Development at CervoMed Inc. (CRVO), received a grant of 30,000 shares (reported as a derivative award) on 2026-02-11. The award was reported at $0.00 per share (no cash purchase). This is a compensation equity award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-11; Form 4 filed 2026-02-13 (accession 0001437749-26-004164).
• Amount and price: 30,000 shares granted at $0.00 (derivative award, transaction code A).
• Vesting: Footnote F1 — underlying common shares vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period, commencing February 28, 2026.
• Shares owned after transaction: Not reported in the details provided in this summary.
• No indication in this filing of a 10b5-1 plan, tax withholding, sale, or late filing flag.

Context This grant is a typical equity compensation award for an executive and will convert to common stock only as portions vest according to the schedule. Such awards are routine for retention and compensation and do not directly signal an immediate buy or sell decision by the insider. Unlike cash purchases, they reflect company compensation practices rather than a personal investment action.